Sano H, Kumagai S, Namiuchi S, Uchiyama T, Yodoi J, Maeda M, Takatsuki K, Suginoshita T, Imura H
Clin Exp Immunol. 1986 Jan;63(1):8-16.
Sera obtained from patients with systemic lupus erythematosus (SLE) were tested for their reactivity to cell lines derived from cutaneous T-cell lymphoma (CTCL), or adult T cell leukaemia (ATL), and with other cell lines, by indirect immunofluorescence method. Approximately one half of SLE sera reacted with the surface antigens of HUT-102 cells, a cell line from CTCL, which constitutively expresses Tac antigen. The titre tended to be higher in the active than in the inactive stage. These positive sera also reacted with other neoplastic or normal T cell lines having Tac antigen. SLE sera reacting with HUT-102 surface antigens were further examined for their reactivities to Tac antigen, the putative IL-2 receptor, using HUT-102 or ATL-2. Pretreatment with anti-Tac monoclonal antibody partially blocked the reactivities to HUT-102 surface antigens in nine of 15 SLE sera tested. The binding of 125I-labelled anti-Tac monoclonal antibody was displaced by the addition of sera from six of 15 SLE patients. In addition, nine of the 15 SLE sera could inhibit the binding of 125I-labelled IL-2 to ATL-2 cells. These results suggested that some of SLE sera contained antibodies against the IL-2 receptor.
采用间接免疫荧光法，检测了系统性红斑狼疮（SLE）患者血清对源自皮肤T细胞淋巴瘤（CTCL）或成人T细胞白血病（ATL）的细胞系以及其他细胞系的反应性。大约一半的SLE血清与源自CTCL的HUT - 102细胞系的表面抗原发生反应，该细胞系组成性表达Tac抗原。在活动期，抗体滴度往往高于非活动期。这些阳性血清也与其他具有Tac抗原的肿瘤性或正常T细胞系发生反应。使用HUT - 102或ATL - 2，进一步检测了与HUT - 102表面抗原发生反应的SLE血清对Tac抗原（假定的IL - 2受体）的反应性。在15份检测的SLE血清中，有9份用抗Tac单克隆抗体预处理后，对HUT - 102表面抗原的反应性部分受到阻断。加入15名SLE患者中6人的血清后，可置换125I标记的抗Tac单克隆抗体的结合。此外，15份SLE血清中有9份可抑制125I标记的IL - 2与ATL - 2细胞的结合。这些结果表明，部分SLE血清含有抗IL - 2受体的抗体。
